Arvinas Inc
NASDAQ:ARVN

Watchlist Manager
Arvinas Inc Logo
Arvinas Inc
NASDAQ:ARVN
Watchlist
Price: 18.73 USD 4.06%
Market Cap: 1.3B USD
Have any thoughts about
Arvinas Inc?
Write Note

Arvinas Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Arvinas Inc
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Arvinas Inc
NASDAQ:ARVN
Cash & Cash Equivalents
$85.2m
CAGR 3-Years
-31%
CAGR 5-Years
48%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Cash & Cash Equivalents
$8.2B
CAGR 3-Years
20%
CAGR 5-Years
15%
CAGR 10-Years
-5%
Bristol-Myers Squibb Co
NYSE:BMY
Cash & Cash Equivalents
$7.9B
CAGR 3-Years
-16%
CAGR 5-Years
-24%
CAGR 10-Years
5%
Pfizer Inc
NYSE:PFE
Cash & Cash Equivalents
$1.1B
CAGR 3-Years
-19%
CAGR 5-Years
-18%
CAGR 10-Years
-8%
Merck & Co Inc
NYSE:MRK
Cash & Cash Equivalents
$14.6B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Cash & Cash Equivalents
$3.4B
CAGR 3-Years
-4%
CAGR 5-Years
17%
CAGR 10-Years
1%
No Stocks Found

Arvinas Inc
Glance View

Market Cap
1.3B USD
Industry
Pharmaceuticals

In the intricate world of biotechnology, Arvinas Inc. emerges as a pioneer, carving out a niche in the realm of targeted protein degradation. Founded by Dr. Craig Crews, the company stands at the forefront of innovation with its PROTAC® (PROteolysis TArgeting Chimeras) technology. This therapeutic approach cleverly harnesses the cell’s natural protein disposal system to degrade disease-causing proteins that have long evaded traditional drug targeting methods. By linking a target protein to an E3 ubiquitin ligase, PROTAC® molecules mark the unwanted proteins for cellular degradation, a strategy that potentially opens up a multitude of targets previously considered "undruggable." This inventive approach not only holds promise for treating a wide spectrum of diseases, including cancer and neurodegenerative disorders, but also positions Arvinas as a leader in redefining therapeutic paradigms. Focusing its business model on partnerships and collaborations, Arvinas has strategically aligned itself with some of the pharmaceutical industry's heavyweights. Revenue streams are derived from these collaborations, which include potential milestone payments, option fees, and royalties linked to the successful commercialization of therapeutics developed through its proprietary PROTAC® technology. By leveraging strategic alliances, Arvinas not only amplifies its research capabilities but also diversifies financial risk. The company is thus uniquely positioned at the intersection of science and commerce, driving innovation while capitalizing on its cutting-edge platform. This dual focus on robust scientific exploration and strategic financial growth creates a compelling narrative for a biotech company aiming to revolutionize disease treatment.

ARVN Intrinsic Value
11.57 USD
Overvaluation 38%
Intrinsic Value
Price

See Also

What is Arvinas Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
85.2m USD

Based on the financial report for Sep 30, 2024, Arvinas Inc's Cash & Cash Equivalents amounts to 85.2m USD.

What is Arvinas Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
48%

Over the last year, the Cash & Cash Equivalents growth was -25%. The average annual Cash & Cash Equivalents growth rates for Arvinas Inc have been -31% over the past three years , 48% over the past five years .

Back to Top